Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pharmacol Ther. Aug 6, 2014; 5(3): 156-168
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156
Table 5 Recomendations for management of patients with cirrhosis
First line therapy | |
Recognize and withdraw all causes of acute kidney disease | |
Resolve primary liver disease | |
Encounter hypoalbuminemia with albumin infusion and tension ascites with repeated paracentesis plus albumin | |
Have a high level of suspicion and treat spontaneous bacterial peritonitis | |
Be vigilant and have into close monitoring patients win acute kidney injury network stage 1 and sCr > 1.5 mg/dL (133 μmol/L) or initial acute kidney injury network stage > 1 | |
If there is no improvement within 2 d, proceed to specific treatment measures | |
Second line therapy | |
Patients hospitalized at the ward | If the diagnosis of hepatorenal syndrome has been placed: |
Give albumin and terlipressin in continuous infusion | |
If there is improvement within 4 d continue with oral midrodrine | |
When terlipressin is unavailable: | |
Give midrodrine plus octreotide plus albumin | |
Patients admitted to intensive care unit | Norepinephrine plus albumin |
Third line therapy | |
Patients who qualify for transplant | Consider liver or simultaneous liver kidney transplantation |
Give therapeutic bridges – Dialysis, transjugular intrahepatic portosystemic shunt | |
Patients who do not qualify for transplant | Continue the combination of terlipressin plus albumin |
Dialysis, TIPS |
- Citation: Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5(3): 156-168
- URL: https://www.wjgnet.com/2150-5349/full/v5/i3/156.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v5.i3.156